Ms. Samira Sakhia reports

KNIGHT THERAPEUTICS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED ACQUISITION OF PALADIN

Knight Therapeutics Inc. has completed the acquisition of the Paladin business, under the terms of the definitive asset purchase agreement (APA) entered with Paladin Pharma Inc., an Endo Inc. operating company, as announced in March, 2025.

On the closing date, Knight paid approximately $107-million in cash, including $22.3-million for the payment of inventory. The payment at closing was reduced by a holdback amount of $15.4-million, of which $10-million may be released under specific conditions and the remaining $5.4-million is expected to be used to settle certain liabilities. In addition, Knight may pay future contingent payments of up to $15-million (U.S.) upon achieving certain sales milestones.

"We are thrilled to announce the successful closing of the Paladin acquisition and look forward to continuing this journey as we integrate our organizations. The combination of Knight's current Canadian business with the Paladin and the Sumitomo portfolios will add critical mass and change the growth trajectory to place Canada as one of the top revenue contributors over the next two years," said Samira Sakhia, president and chief executive officer of Knight. "In addition, having closed both Paladin and Sumitomo, as well as the revolving line of credit, we remain well positioned to continue to transact and execute on our mission to acquire, in-license, develop and commercialize pharmaceutical products in Latin America and Canada."

RBC Capital Markets is serving as exclusive financial adviser to Knight, and Davies Ward Phillips & Vineberg is serving as Knight's legal counsel.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics's shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.